Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Core Insights - Molecular Partners AG has made significant advancements in 2024, particularly in the development of its Radio-DARPins and next-generation immuno-oncology programs, positioning the company for key value inflection points [2][3] - The company reported a total revenue of CHF 5.0 million for 2024, a decrease from CHF 7.0 million in 2023, while total operating expenses were CHF 66.2 million, down from CHF 68.1 million in the previous year [24][28] Research & Development Highlights - The IND application for MP0712, a Pb Radio-DARPin therapy targeting DLL3, is in preparation, with submission anticipated in H1 2025 [4][5] - The second RDT program targeting mesothelin (MSLN) is also in development, with initial preclinical data to be presented at the AACR in Q2 2025 [6][8] - MP0533, a multispecific T cell engager, is undergoing a Phase 1/2a clinical trial for relapsed/refractory acute myeloid leukemia (AML), with data on an amended dosing scheme expected in 2025 [12][14] Financial Highlights - The company raised approximately $20 million in October 2024 to support the development of its radiopharmaceutical pipeline [23] - As of December 31, 2024, cash and cash equivalents totaled CHF 149.4 million, sufficient to fund operations into 2027 [26] - The net loss for 2024 was CHF 54.0 million, an improvement from a net loss of CHF 62.0 million in 2023 [24][28] Corporate Governance & Leadership - Philippe Legenne was appointed Chief Medical Officer in August 2024, bringing significant clinical experience to the company [21] - A putative class action complaint against the company was dismissed in February 2024, closing the case in the company's favor [22] Strategic Partnerships - The strategic partnership with Orano Med has been expanded to co-develop up to ten radiotherapy programs, with Molecular Partners retaining commercialization rights to MP0712 and the MSLN RDT program [9][11]